SAN ANTONIO, June 6, 2016 /PRNewswire/ -- At the 64th ASMS
Conference, Bruker announces the launch of the new rapifleX™
MALDI PharmaPulse™ (MPP) solution. It is
the latest addition to Bruker's portfolio of innovative products
designed to assist pharmaceutical, biotech and CRO customers to
accelerate drug discovery, and rapifleX MPP can dramatically
lower the cost of ultra-high throughput screening (uHTS) with
further improved results.
![Figure 1: rapifleX MPP completes the analyses of a 1,536 mtp in less than 8 minutes and is also compatible with a 6,144 mtp. Figure 1: rapifleX MPP completes the analyses of a 1,536 mtp in less than 8 minutes and is also compatible with a 6,144 mtp.](https://photos.prnewswire.com/prnvar/20160603/375395)
Ultra-high throughput screening today is primarily performed by
fluorescence techniques, which require labeled compounds. Mass
spectrometry offers label-free screening, and inherently reduces or
avoids false positives, making expensive and time-consuming hit
qualification redundant. However, for large screening
campaigns of millions of samples, mass spectrometry so far could
not offer the required speed and robustness. The new
rapifleX MPP solution is the first robust, ultra-high
throughput mass spectrometer which offers the speed, specificity
and robustness of mass spectrometry for large primary screens.
Dr. Jens Höhndorf, Head of Bruker
Daltonics Instrument R&D, commented: "The new rapifleX
MPP is the result of Bruker's innovative development of MALDI
mass spectrometers. It reflects our passion for and knowledge about
this technology and its unique applications. The rapifleX
MALDI-TOF with its new 10 kHz scanning laser technology,
enhanced sensitivity and exceptional robustness-by-design opens
entirely new applications for MALDI mass spectrometry and allows
our customers to improve their existing applications, especially
for molecular MALDI mass-spec imaging (MSI) and now also for
MALDI-uHTS."
About the rapifleX MALDI
PharmaPulse Solution
As a dedicated uHTS solution to accelerate drug discovery, the
rapifleX MPP provides numerous advantages over
traditional technologies. Its label-free detection of substrates
and products accelerates assay development, reduces complexity of
screening, and avoids artifacts from interferences with the labels
used in traditional uHTS technologies.
W. Adam Hill, D. Phil., Founder
and Chief Scientific Officer of Prospective Research, Inc. in
Beverly, Massachusetts, stated:
"The MALDI PharmaPulse solution has demonstrated impact on
drug discovery today, by providing a robust, label free, multiplex
capable solution at high throughput. The introduction of
rapifleX is an important extension, bringing MALDI
PharmaPulse to ultra-high throughput speeds and increasing the
robustness of the platform for large screens."
Compared to existing LC/SPE-MS HTS solutions, the rapiflex
MPP is 100-1000x faster and uses about 100x less solvent,
without the need for LC columns and other LC consumables.
Based on Bruker's proprietary new 10 kHz smartbeam® 3D
laser system developed for the rapifleX, and incorporating a
new integrated microtitre plate (mtp) sample changer and HTS
automation solutions (e.g. robotics and automation software from
HighRes Biosolutions, Woburn, MA),
this is the first mass-spectrometry based, label-free uHTS
solution, using standard 1,536 mtps, or even the latest 6,144 mtps.
The rapifleX MPP completes the analyses of a
1,536 mtp in less than 8 minutes, and due to its extreme robustness
is ideally suited for primary screens of millions of compounds,
with significantly lower cost per sample and unprecedented primary
screen 'true hit' rates.
About the Bruker Corporation
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance
scientific research instruments and high-value analytical solutions
enable scientists to explore life and materials at molecular,
cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, in
microscopy, nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit: www.bruker.com
Photo - http://photos.prnewswire.com/prnh/20160603/375395
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bruker-launches-rapiflex-maldi-pharmapulse-solution-for-uhts-300279632.html
SOURCE Bruker Corporation